Company Analysis
Sign in

ProQR Therapeutics N.V. (PRQR)

Nasdaq: PRQR · Pharmaceutical Preparations · Leiden, NL · filing with the SEC since 2014
Full chart Alerts Compare
Grade5.2
◀ Past 6.6● Present 4.7▶ Future 4.8
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

24 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to ProQR Therapeutics N.V.’s names, not what it holds today.

Patents granted
24
24 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 4 in 2024 and 3 in 2023
Applications published
51
4 of them in 2025
Names they are printed under
3
a subsidiary, its own name
By yearGrantedApplications published
'15'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals10
Biotechnology7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
ProQR Therapeutics II B.V. a subsidiary
named as the applicant on its applications, in NL
0 granted
38 published
ProQR Therapeutics II B.V. a subsidiary
NL, as the owner printed on each patent
24 granted
11 published
ProQR Therapeutics N.V. its own name
named as the applicant on its applications, in NL
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 26, 202512,398,393RNA-editing oligonucleotides for the treatment of usher syndromeBiotechnologyProQR Therapeutics II B.V.
Apr 15, 202512,275,937Stereospecific linkages in RNA editing oligonucleotidesBiotechnologyProQR Therapeutics II B.V.
Jan 21, 202512,203,072Chemically modified single-stranded rna-editing oligonucleotidesPharmaceuticalsProQR Therapeutics II B.V.
Dec 31, 202412,180,471Antisense oligonucleotides for the treatment of Stargardt diseaseBiotechnologyProQR Therapeutics II B.V.
Jun 25, 202412,018,257Single-stranded RNA-editing oligonucleotidesPharmaceuticalsProQR Therapeutics II B.V.
Mar 5, 202411,920,132Oligonucleotide therapy for Leber congenital amaurosisPharmaceuticalsProQR Therapeutics II B.V.
Jan 9, 202411,866,702Nucleic acid molecules for pseudouridylationBiotechnologyProQR Therapeutics II B.V.
Dec 26, 202311,851,656Chemically modified single-stranded RNA-editing oligonucleotidesPharmaceuticalsProQR Therapeutics II B.V.
Oct 10, 202311,781,134Targeted RNA editingBiotechnologyProQR Therapeutics II B.V.
May 16, 202311,649,454Single-stranded RNA-editing oligonucleotidesPharmaceuticalsProQR Therapeutics II B.V.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0333734Antisense oligonucleotides for the treatment of Stargardt diseaseBiotechnologyProQR Therapeutics II B.V.
Oct 2, 20252025/0304962STEREOSPECIFIC LINKAGES IN RNA EDITING OLIGONUCLEOTIDESBiotechnologyProQR Therapeutics II B.V.
Jul 10, 20252025/0223593CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDESPharmaceuticalsProQR Therapeutics II B.V.
May 15, 20252025/0154504GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIABiotechnologyProQR Therapeutics II B.V.
Dec 19, 20242024/0417721SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDESPharmaceuticalsProQR Therapeutics II B.V.
Aug 15, 20242024/0271131CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDESPharmaceuticalsProQR Therapeutics II B.V. · patent 12,203,072 granted from it
Jul 11, 20242024/0229030NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATIONBiotechnologyProQR Therapeutics II B.V.
May 2, 20242024/0141340ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF CORNEAL DYSTROPHIESBiotechnologyProQR Therapeutics II B.V.
May 2, 20242024/0141336TARGETED RNA EDITINGBiotechnologyProQR Therapeutics II B.V.
Apr 25, 20242024/0132890NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATIONBiotechnologyProQR Therapeutics II B.V.
What it applied for, 2024 to 2025: Biotechnology 7 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PRQR · research, not advice